Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice

European Journal of Vascular and Endovascular Surgery

Volumn 26, Issue 1, 2003, Pages 88-95

  Ezzahiri, R ^a   Stassen, F R M ^a   Kurvers, H A J M ^a   van Pul, M M ^a   Kitslaar, P J E H M ^a   Bruggeman, C A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chlamydia pneumoniae; Fibrous cap area; Matrix metalloproteinases; Unstable plaques

Indexed keywords

APOLIPOPROTEIN E; BACTERIAL DNA; GELATINASE A; GELATINASE B; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; HISTOPATHOLOGY; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROCONVERSION; TISSUE SECTION;

EID: 0038489423     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.2002.1913     Document Type: Article

References (30)

1. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
2. Wiesli P, Czerwenka W, Meniconi A et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation 2002; 105: 2646-2652.
3. Heuschmann PU, Neuretter D, Gesslein M et al. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke 2001; 32: 2253-2258.
4. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986.
5. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000; 321: 204-207.
6. Chandra HR, Choudhary N, O'Neill C, Boura J, Timmis GC, O'Neill WW. Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). Am J Cardiol 2001; 88: 214-218.
7. Blessing E, Kuo CC, Lin TM et al. Foam cell formation inhibits growth of Chlamydia pneumoniae but does not attenuate Chlamydia pneumoniae-induced secretion of proinflammatory cytokines. Circulation 2002; 105: 1976-1982.
8. Sasu S, Laverda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89: 244-250.
9. Vehmaan-Kreula P, Puolakkainen M, Sarvas M, Welcus HG, Kovanen PT. Chlamydia pneumoniae proteins induce secretion of the 92-kDa gelatinase by human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2001; 21: E1-E8.
10. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-307.
11. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999; 180: 238-241.
12. Muhlestein JB, Anderson JL, Hammond EH et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-636.
13. Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 1995; 15: 1512-1531.
14. Ezzahiri R, Nelissen-Vrancken H, Kurvers H et al. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates formation of complex atherosclerotic lesion in Apo E3-Leiden mice. Cardiovasc Res 2002; 56: 269-276.
15. Bloemenkamp DG, Mali WP, Tanis BC et al. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. Atherosclerosis 2002; 163: 149-156.
16. Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: The Northern Manhattan Stroke Study. Stroke 2000; 31: 1521-1525.
17. Roblin PM, Dumornay W, Hammerschlag MR. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J Clin Microbiol 1992; 30: 1968-1971.
18. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-753.
19. Lutgens E, Daemen M, Kockx M et al. Atherosclerosis in APOE*3-Leiden transgenic mice: from proliferative to atheromatous stage. Circulation 1999; 99: 276-283.
20. Tong CY, Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993; 46: 313-317.
21. Aalto-Setala K, Laitinen K, Erkkila L et al. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 578-584.
22. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001; 103: 2834-2838.
23. Song YG, Kwon HM, Kim JM et al. Serologic and histopathologic study of Chlamydia pneumoniae infection in atherosclerosis: a possible pathogenetic mechanism of atherosclerosis induced by Chlamydia pneumoniae. Yonsei Med J 2000; 41: 319-327.
24. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 1998; 177: 1322-1325.
25. Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-2146.
26. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997; 17: 1859-1867.
27. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
28. Rosenfeld ME, Polinsky F, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol 2000; 20: 2587-2592.
29. Shah P, Falk E, Badimon J et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569.
30. Lutgens E, Gijbels M, Smook M et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-982.